Canada · Delayed Price · Currency is CAD Bright Minds Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
BMB-101 demonstrated strong efficacy and safety in refractory seizure disorders, with phase III trials in epilepsy and Prader-Willi syndrome underway. Both indications are seen as multi-billion dollar opportunities, and recent financing supports multiple upcoming clinical readouts.
-
BMB-101 showed robust efficacy and safety in highly refractory adults with absence seizures and DEE, achieving up to 73% median reduction in absence seizures and 63% in major motor seizures, with a favorable tolerability profile and practical dosing. These results support advancement to global registrational studies.
Fiscal Year 2025
-
The company is advancing a differentiated 5-HT2C agonist in phase II for DEE and Absence Epilepsy, with strong biomarker and QEEG support, and is expanding into Prader-Willi syndrome. Pivotal trials are planned for next year, with all current programs fully funded.
-
Experts highlighted the urgent need for comprehensive PWS therapies, emphasizing the potential of 5-HT2C agonists to address both metabolic and neurobehavioral symptoms. The clinical program leverages robust preclinical and early clinical data, validated outcome measures, and a strategic trial design to differentiate from existing treatments.